<code id='CDE43EC247'></code><style id='CDE43EC247'></style>
    • <acronym id='CDE43EC247'></acronym>
      <center id='CDE43EC247'><center id='CDE43EC247'><tfoot id='CDE43EC247'></tfoot></center><abbr id='CDE43EC247'><dir id='CDE43EC247'><tfoot id='CDE43EC247'></tfoot><noframes id='CDE43EC247'>

    • <optgroup id='CDE43EC247'><strike id='CDE43EC247'><sup id='CDE43EC247'></sup></strike><code id='CDE43EC247'></code></optgroup>
        1. <b id='CDE43EC247'><label id='CDE43EC247'><select id='CDE43EC247'><dt id='CDE43EC247'><span id='CDE43EC247'></span></dt></select></label></b><u id='CDE43EC247'></u>
          <i id='CDE43EC247'><strike id='CDE43EC247'><tt id='CDE43EC247'><pre id='CDE43EC247'></pre></tt></strike></i>

          Home / explore / hotspot

          hotspot


          hotspot

          author:explore    Page View:231
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In